• About Us
    • Contact Us
    • Login
    • ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
About Us Contact Us Login ObGFirst
  • COVID-19
  • Alerts
  • OB
  • 2T US Atlas
  • The Genome
  • GYN
    • 0 CME Hours
    • GYN
    • Sexual Health
  • Primary Care
  • Your Practice
  • #GrandRounds
  • My Bookshelf
  • Now@ObG
  • Media
#Grand Rounds

The UKOSS COVID-19 Pregnancy Registry: Update on 427 Patients Admitted to Hospital

image_pdfFavoriteLoadingFavorite

PURPOSE:

  • The UK Obstetric Surveillance System (UKOSS) is a research registry system, funded by the National Institute for Health Research in 2012 to prepare in case of a pandemic
    • Due to COVID-19, UKOSS was activated in March 2020
  • Researchers based at the University of Oxford, in collaboration with RCOG, the Universities of Leeds and Birmingham, Kings and Imperial Colleges London studied the current risk factors and outcomes among pregnant women with SARS-CoV-2 infection who were hospitalized on maternity units from all 194 hospitals in the UK

METHODS:

  • UKOSS National prospective observational cohort study (March 1 to April 14, 2020)
  • Participants (exposed group)
    • Pregnant women admitted to hospital with confirmed SARS-CoV-2 infection
  • Comparison cohort
    • 2 women giving birth immediately prior to any woman with confirmed influenza (derived from a previous study that analyzed influenza in pregnancy between November 1, 2017 and October 30, 2018)
    • This comparison (control) cohort was used to avoid confusing ‘non-SARS-CoV-2’ patients with those who may be infected but were asymptomatic
  • Primary outcome
    • Incidence of maternal hospitalization and infant infection
    • Rates of maternal death, level 3 critical care unit admission, preterm birth, stillbirth, early neonatal death, perinatal death
  • Statistical analysis
    • Based on number of patients in study and comparison cohort: 80% power at p<0.05 could detect a ≥1.5 difference of a more common risk factor (with 25% prevalence in comparison group) and ≥2 difference for a risk factor with 5% prevalence

RESULTS:

  • Study cohort: n=427 | Comparison group: n= 694 women
    • Most common presenting symptoms were fever, cough, and breathlessness
    • 247 (58%) gave birth or had a pregnancy loss | Remaining 180 (42%) of cases are ongoing
  • Estimated incidence of hospitalization with confirmed SARS-CoV-2 in pregnancy: 4.9/1000 maternities (95% CI, 4.5 to 5.4)
  • The median gestation at symptom onset: 34 weeks (IQR 29- 38)
    • Admission during 3rd trimester or peripartum: 81%
  • Risk factors for admission during pregnancy
    • Black or other minority ethnicity: 46% | Adjusted odds ratio (aOR) 4.49 (95% CI, 3.37 to 6.00)
    • Older maternal age (>35 years): aOR 1.35 (95% CI, 1.01 to 1.81)
    • Overweight (BMI ≥25): aOR 1.91 (95% CI, 1.37 to 2.68)
    • Obesity (BMI ≥30): aOR 2.20 (95% CI, 1.56 to 3.10)
    • Preexisting Medical Condition: aOR 1.52 (95% CI, 1.12 to 2.06) | Included asthma, hypertension, cardiac disease and diabetes
    • Patients were less likely to be smokers
  • Of patients giving birth during the study, 75% delivered at term
  • Preterm: 66 patients
    • 80% were iatrogenic: 48% due to maternal COVID-19 | 14% due to fetal compromise | 18% for other obstetric conditions
  • Cesarean: 59%
    • Maternal compromise: 27%
    • Fetal compromise: 24%
    • Failure to progress or failed induction: 19%
    • Other obstetrical reasons: 15%
    • Previous cesarean: 11%
    • Maternal request: 4%
  • Mothers requiring respiratory support: 10% (41 women) | 4 women required ECMO
    • Maternal case fatality: 1.2% (95% CI, 0.4% to 2.7%)
    • 3 women died of COVID-19 related complications
  • Infants testing positive for SARS-CoV-2: 5% (12 infants) | 6 within 12 hours after birth | 4 delivered by cesarean including 3 pre-labor
  • Fetal and newborn loss
    • Miscarriage: 4 (0.9% of admitted patients) between 10 and 19 weeks
    • Stillbirth: 3 (1 stillbirth not related to COVID-19; 2 stillbirths unclear if COVID-19 related)
    • Neonatal deaths: 2 (definitely not related to COVID-19)
  • Newborn ICU admission: 25% of liveborn infants
    • Preterm: 75%
  • Newborn SARS-CoV-2 testing
    • Infants testing positive: 5% (n=12)
    • Early onset (within 12 hours): 6 infants
      • Vaginal delivery: 2
      • Cesarean: 4 (3 prelabor)
      • Admitted to NICU: 1
    • Later onset (>12 hours): 6 infants
      • Prelabor caesarean: 4
      • Vaginal delivery: 2
      • Admitted to NICU: 5

CONCLUSION:

  • Most patients had good outcomes that generally tracked with general non-pregnant population
    • Clinical course: 10% required ventilatory support
    • Risk factors: Strong association with comorbidities
  • Transmission uncommon but may occur
  • Hospitalizations were in late second and third trimester
  • >60% cesarean rate: Majority for indications other than maternal compromise due to COVID-19
  • The authors emphasize the association between black or minority ethnicity groups and hospitalization for COVID-19
    • This association was not explained by geography and remained after adjusting for age, BMI and co-morbidities and “is of concern and requires further investigation”

Learn More – Primary Sources:

Characteristics and outcomes of pregnant women hospitalised with confirmed SARS-CoV-2 infection in the UK: a national cohort study using the UK Obstetric Surveillance System (UKOSS)

RCOG and RCM respond to UKOSS study of more than 400 pregnant women hospitalised with coronavirus

Get Essential Research Summaries Direct to Your Phone, with ObGFirst

Try it Free »

image_pdfFavoriteLoadingFavorite
< Previous
All #Grand Rounds Posts
Next >

Related ObG Topics:

SMFM Guideline Update on COVID-19 in Pregnancy
ACOG COVID-19 FAQs for Obstetrical Care
Coronavirus and Pregnancy: CDC Guidance and Professional Recommendations

Sections

  • COVID-19
  • Alerts
  • OB
  • GYN
    • GYN
    • Sexual Health
  • 2T US Atlas
  • The Genome
  • Primary Care
  • Your Practice
  • #Grand Rounds
  • My Bookshelf
  • Now@ObG
  • Media

ObG Library

  • Hysteroscopy
  • Fertility
  • Site Map/
  • © ObG Project/
  • Terms and Conditions/
  • Privacy/
  • Contact Us/
© ObG Project
SSL Certificate


  • Already an ObGFirst Member?
    Welcome back

    Log In

    Want to sign up?
    Get guideline notifications
    CME Included

    Sign Up

Get Guideline Alerts Direct to Your Phone
Try ObGFirst Free!

Sign In

Lost your password?

Sign Up for ObGFirst and Stay Ahead

  • - Professional guideline notifications
  • - Daily summary of a clinically relevant
    research paper
  • - Includes 1 hour of CME every month

ObGFirst Free Trial

Log In to ObG First

Please log in to access OBGFirst and the 2T Ultrasound Atlas

Password Trouble?

Sign Up for ObGFirst

  • - Access 2T US Atlas
  • - Guideline notifications
  • - Daily research paper summaries
  • - And lots more!

ObG First Free Trial

Media - Internet

Computer System Requirements

OBG Project CME requires a modern web browser (Internet Explorer 10+, Mozilla Firefox, Apple Safari, Google Chrome, Microsoft Edge). Certain educational activities may require additional software to view multimedia, presentation, or printable versions of their content. These activities will be marked as such and will provide links to the required software. That software may be: Adobe Flash, Apple QuickTime, Adobe Acrobat, Microsoft PowerPoint, Windows Media Player, or Real Networks Real One Player.

Disclosure of Unlabeled Use

This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications.

The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.

Disclaimer

Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information
presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.

Jointly provided by

NOT ENOUGH CME HOURS

It appears you don't have enough CME Hours to take this Post-Test. Feel free to buy additional CME hours or upgrade your current CME subscription plan

Subscribe

JOIN OBGFIRST AND GET CME/CE CREDITS

One of the benefits of an ObGFirst subscription is the ability to earn CME/CE credits from the ObG entries you read. Tap the button to learn more about ObGFirst

Learn More
Leaving ObG Website

You are now leaving the ObG website and on your way to PRIORITY at UCSF, an independent website. Therefore, we are not responsible for the content or availability of this site